A quasi-monomode guided atom-laser from an all-optical Bose-Einstein condensate

We report the achievement of an optically guided and quasi-monomode atom laser, in all spin projection states ($m_F =$ -1, 0 and $+1$) of F=1 in Rubidium 87. The atom laser source is a Bose-Einstein condensate (BEC) in a crossed dipole trap, purified to any one spin projection state by a spin-distillation process applied during the evaporation to BEC. The atom laser is outcoupled by an inhomogenous magnetic field, applied along the waveguide axis. The mean excitation number in the transverse modes is $= 0.65 \pm 0.05$ for $m_F = 0$ and $= 0.8 \pm 0.3$ for the low field seeker $m_F = -1$

Ultrarobust calibration of an optical lattice depth based on a phase shift

We report on a new method to calibrate the depth of an optical lattice. It consists in triggering the intrasite dipole mode of the cloud by a sudden phase shift. The corresponding oscillatory motion is directly related to the intraband frequencies on a large range of lattice depths. Remarkably, for a moderate displacement, a single frequency dominates this oscillation for the zeroth and first order interference pattern observed after a sufficiently long time-of-flight. The method is robust against atom-atom interactions and the exact value of the extra external confinement of the initial trapping potential.Comment: 7 pages, 6 figure

Optimal transport of ultracold atoms in the non-adiabatic regime

We report the transport of ultracold atoms with optical tweezers in the non-adiabatic regime, i.e. on a time scale on the order of the oscillation period. We have found a set of discrete transport durations for which the transport is not accompanied by any excitation of the centre of mass of the cloud. We show that the residual amplitude of oscillation of the dipole mode is given by the Fourier transform of the velocity profile imposed to the trap for the transport. This formalism leads to a simple interpretation of our data and simple methods for optimizing trapped particles displacement in the non-adiabatic regime

Comparative Analysis of Legislative Requirements About Patients' Access to Biotechnological Drugs for Rare Diseases in Central and Eastern European Countries

Objectives: The aim of the study was to compare the access of patients with rare diseases (RDs) to biotechnological drugs in several Central and Eastern European countries (CEECs). We focused on the legislative pricing and reimbursement requirements, availability of biotechnological orphan medicinal products (BOMPs) for RDs, and reimbursement expenditures. Methods: A questionnaire-based survey was conducted among experts from 10 CEECs: Bulgaria, Croatia, Estonia, Greece, Hungary, Poland, Romania, Slovakia, Serbia, and Macedonia. The legal requirements for reimbursement and pricing of BOMPs were collected. All BOMPs and medicines without prior orphan designations were extracted from the European list of orphan medicinal products, 2017. The reimbursement status of these medicinal products in 2017 in the public coverage of the included CEECs as well as the share of their costs in relation to the total public pharmaceutical spending for the period from 2014 to 2016 were defined. Results: Our survey revealed that some differences in the legal requirements for pricing and reimbursement of BOMPs amongst the countries included in the study. All European Union countries have developed and implemented pharmacoeconomic guidelines with or without some specific reimbursement requirements for orphan medicinal products. Cost-effectiveness analysis, cost-utility analysis, Markov models, meta-analysis, and discount levels of costs and results were required only in Bulgaria, Poland and Hungary. The number of reimbursed BOMPs and biotechnological medicinal products for RDs without prior orphan designation was the highest in Hungary (17 and 40, respectively). Patient-based reimbursement schemes were available only in Hungary for 11 out of 17 BOMPs. Poland and Greece have the highest pharmaceutical expenditure of reimbursed BOMPs with are similar to 214 million and 180 million EUR, respectively in the observed period from 2014 to 2016. High proportion of the pharmaceutical expenditure on the reimbursed biotechnological medicinal products for RDs for the observed period 2014-2016 is presented in Bulgaria and Slovakia. Conclusions: The non-European Union CEECs face a significant delay in the legal implementation of pharmacoeconomic guideline for assessment of BOMPs. The access to BOMPs is similar among the observed CEECs and the countries with the best access are Hungary and Greece. The influence of BOMP expenditures on the budget in the individual countries is significant

The Efficacy of Trastuzumab in Animal Models of Breast Cancer:A Systematic Review and Meta-Analysis

BACKGROUND:Breast cancer is the most frequent cancers and is the second leading cause of cancer death among women. Trastuzumab is an effective treatment, the first monoclonal antibody directed against the human epidermal growth factor receptor 2 (HER2). To inform the development of other effective treatments we report summary estimates of efficacy of trastuzumab on survival and tumour volume in animal models of breast cancer. METHODS:We searched PubMed and EMBASE systematically to identify publications testing trastuzumab in animal models of breast cancer. Data describing tumour volume, median survival and animal features were extracted and we assessed quality using a 12-item checklist. We analysed the impact of study design and quality and evidence for publication bias. RESULTS:We included data from 83 studies reporting 169 experiments using 2076 mice. Trastuzumab treatment caused a substantial reduction in tumour growth, with tumours in treated animals growing to 32.6% of the volume of tumours in control animals (95%CI 27.8%-38.2%). Median survival was prolonged by a factor of 1.45 (1.30-1.62). Many study design and quality features accounted for between-study heterogeneity and we found evidence suggesting publication bias. CONCLUSION:We have found trastuzumab to be effective in animal breast cancer models across a range of experimental circumstances. However the presence of publication bias and a low prevalence of measures to reduce bias provide a focus for future improvements in preclinical breast cancer research